Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 311       
Year : 2018  |  Volume : 148  |  Issue : 3  |  Page : 263-278

A fascinating story of the discovery & development of biologicals for use in clinical medicine

1 Department of Rheumatology, ISIC Superspeciality Hospital, New Delhi, India
2 Former Head, Department of Transplant Immunology & Immunogenetics, All India Institute of Medical Sciences, New Delhi, India

Correspondence Address:
Dr Anand N Malaviya
Department of Rheumatology, ISIC Superspeciality Hospital, Vasant Kunj, New Delhi 110 070
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijmr.IJMR_1471_18

Rights and Permissions

A young physician starting a fresh career in medicine in this millennium would hardly stop to think about the genesis of a particular biological drug that he/she will be prescribing for a patient evaluated in the morning outpatient department. For him/her, this is now routine, and the question of ‘Who’, ‘How’ and ‘When’ about these biologicals would be the last thing on their mind. However, for those who came to the medical profession in the 1950s, 1960s and 1970s, these targeted drugs are nothing short of ‘miracles’. It would be a fascinating story for the young doctor to learn about the long journey that the dedicated biomedical scientists of yesteryears took to reach the final destination of producing such wonder drugs. The story is much like an interesting novel, full of twists and turns, heart-breaking failures and glorious successes. The biologicals acting as ‘targeted therapy’ have not only changed the natural history of a large number of incurable/uncontrollable diseases but have also transformed the whole approach towards drug development. From the classical empirical process, there is now a complete shift towards understanding the disease pathobiology focusing on the dysregulated molecule(s), targeting them with greater precision and aiming for better results. Seminal advances in understanding the disease mechanism, development of remarkably effective new technologies, greater knowledge of the human genome and genetic medicine have all made it possible to reach the stage where artificially developed ‘targeted’ drugs are now therapeutically used in routine clinical medicine.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded560    
    Comments [Add]    
    Cited by others 1    

Recommend this journal